142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

308946
A comprehensive picture of the antimalarial medicine market in five countries: Findings from Cambodia, Democratic Republic of Congo, Madagascar, Nigeria, and Uganda

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Monday, November 17, 2014

Vamsi Vasireddy, MD, MPH, DrPH , Centers for Disease Control and Prevention (CDC), Dar es Salaam, Tanzania
Kevin Duff, MPH, MSc , ACTwatch, Population Services International, Nairobi, Kenya
Julius Njogu, Bsc , ACTwatch, Population Services International, Nairobi, Kenya
Raymond Sudoi, Mr. , ACTwatch, Population Services International, Nairobi, Kenya
Julie Archer , Population Services International, Nairobi, Kenya
John Rogers, PhD, MPH , ACTwatch, Population Services International, Nairobi, Kenya
Background:

ACTwatch is a multi-country research project designed to fill evidence gaps on malaria diagnostics, antimalarial medicines, and fever case management in the private and public sectors. It is being implemented across ten countries - Benin, Cambodia, Democratic Republic of Congo (DRC), Kenya, Madagascar, Myanmar, Nigeria, Tanzania, Uganda, and Zambia.

Material and methods:

Cross-sectional studies are conducted nationally to describe the availability, price and market share of antimalarial medicines, and the availability and price of rapid diagnostic tests (RDTs) for malaria among outlets. Studies were conducted in Benin, DRC, Madagascar, Nigeria, and Uganda in 2013. The antimalarials and diagnostic testing data is classified according the type of outlet and the different classes of antimalarials and diagnostics.

Results:

Antimalarials are classified according to Quality-Assured Artemisinin Combination Treatments (QAACT), which are the preferred medicines, other ACTs, oral Artemisinin Monotherapies, Chloroquine, Quinine, and Sulfadoxine-Pyrimethamine (SP). Trend data will be presented from data collection points in 2009, 2011, and 2013. For example: In Uganda, overall availability of ACT increased from 34% to 75% from 2009 to 2011. 2013 data is currently being cleaned and analyzed for distribution in Summer 2014.

Conclusions

Given the well-documented role of the private sector as a treatment source in sub-Saharan Africa and Asia, timely data on the availability, price and market share for antimalarials and diagnostics can help inform programming and health promotion campaigns. ACTwatch provides researchers, donors, and governments detailed data on RDT and ACT availability, with the potential to inform programs and improve access.

Learning Areas:

Conduct evaluation related to programs, research, and other areas of practice
Other professions or practice related to public health
Protection of the public in relation to communicable diseases including prevention or control
Public health or related organizational policy, standards, or other guidelines
Public health or related public policy
Public health or related research

Learning Objectives:
Describe the availability, price, and market share of antimalarial medicines available in Cambodia, Democratic Republic of Congo, Madagascar, Nigeria, and Uganda. Describe the availability and price of diagnostic testing for malaria in Cambodia, Democratic Republic of Congo, Madagascar, Nigeria, and Uganda. Describe the methods used to evaluate the availability, price, and market share of antimalarial medicines and diagnostic testing for malaria. Discuss the policy implications of the presented data. Compare the antimalarial markets across different countries.

Keyword(s): International Health, Research

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been working with the ACTwatch project for the last year managing multiple nationally representative surveys. I have also worked as a public health professional conducting community health needs assessments, quality of care evaluations and data analysis consultancy work. My main research interests include antimalarial resistance containment and antimalarial medicine and malaria diagnostics availability, price and market share.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.